Determinants of malaria diagnostic uptake in the retail sector: qualitative analysis from focus groups in Uganda by Cohen, Jessica et al.
Determinants of malaria diagnostic
uptake in the retail sector: qualitative
analysis from focus groups in Uganda
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Cohen, Jessica, Alex Cox, William Dickens, Kathleen Maloney, Felix
Lam, and Günther Fink. 2015. “Determinants of malaria diagnostic
uptake in the retail sector: qualitative analysis from focus groups in
Uganda.” Malaria Journal 14 (1): 89. doi:10.1186/s12936-015-0590-x.
http://dx.doi.org/10.1186/s12936-015-0590-x.
Published Version doi:10.1186/s12936-015-0590-x
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:14065386
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH Open Access
Determinants of malaria diagnostic uptake in the
retail sector: qualitative analysis from focus
groups in Uganda
Jessica Cohen1*, Alex Cox1, William Dickens2, Kathleen Maloney3, Felix Lam4 and Günther Fink1
Abstract
Background: In Uganda, as in most other malaria-endemic countries, presumptive treatment for malaria based on
symptoms without a diagnostic blood test is still very common. While diagnostic testing in public sector facilities is
increasing, many people in Uganda who suspect malaria visit private sector outlets to purchase medications. Increasing
the availability and uptake of rapid diagnostic tests (RDTs) for malaria in private outlets could help increase diagnostic
testing for malaria but raises questions about the patient demand for and valuation of testing that are less critical for
public sector introduction.
Methods: In preparation for a behaviour change campaign to encourage and sustain the demand for RDTs in drug
shops, eight focus group discussions with a total of 84 community members were conducted in six districts across
Uganda’s Eastern Region in November-December 2011. Focus groups explored incentives and barriers to
seeking diagnosis for malaria, how people react to test results and why, and what can be done to increase
the willingness to pay for RDTs.
Results: Overall, participants were very familiar with malaria diagnostic testing and understood its
importance, yet when faced with limited financial resources, patients preferred to spend their money on
medication and sought testing only when presumptive treatment proved ineffective. While side effects did
seem to be a concern, participants did not mention other potential costs of taking unnecessary or ineffective
medications, such as money wasted on excess drugs or delays in resolution of symptoms. Very few
individuals were familiar with RDTs.
Conclusion: In order to boost demand, these results suggest that private sector RDTs will have to be made
convenient and affordable and that targeted behaviour change campaigns should strive to increase the
perceived value of diagnosis.
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Background
The continued reliance on presumptive treatment for
malaria means that many patients receive an incorrect
diagnosis of malaria and inappropriate treatment for the
actual cause of their illness [1-3]. In addition to poor pa-
tient management, presumptive treatment and the ensu-
ing over-treatment of malaria with artemisinin-based
anti-malarials represents a waste of private and public
resources and could increase the risk of the emergence
of resistant parasite strains [4,5]. In response, in 2010,
the World Health Organization (WHO) changed its
fever case management guidelines to recommend that
artemisinin-based combination therapy (ACT) be used
only in patients that have a blood test diagnosis of mal-
aria when possible. Following this guideline change,
many countries aligned their national strategy with the
WHO recommendation and began to scale-up access to
diagnostic technology in their public sector [6].
Great progress has been made in the public sector;
confirmation of malaria cases in the public sector has
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increased from less than 10 to over 60% between 2000
and 2013 in the WHO African Region [7]. However, in
the private sector, uptake of malaria diagnostics has
remained at much lower levels [7,8]. A study from six
African countries found that only 2 to 16% of children
with febrile illnesses received a malaria blood test in the
private sector prior to treatment [9]. Purchasing over-
the-counter medication from a pharmacy or drug shop
without first seeking professional medical advice is a
very common response to fever episodes in sub-Saharan
Africa [9-11]. Treatment-seeking in the retail sector is
common because health facilities are often distant, with
limited staff, long wait times, limited hours, and frequent
stock-outs of essential medicines. Even when fees at
public health facilities are low, visits to private or infor-
mal drug shops are common due to their convenience
and accessibility [12].
The heavy reliance on drug shops and other private
outlets has led the malaria community to consider ways
of leveraging this sector to improve fever case manage-
ment [13,14]. The Affordable Medicines Facility-malaria
(AMFm) initiative, piloted in seven countries in 2010, is
one example. The AMFm was an innovative financing
mechanism designed to increase access to high-quality
ACT through a donor-funded subsidy for ACT and sup-
porting interventions. Results from the AMFm inde-
pendent evaluation (IE) suggest that the private sector
can be an efficient partner to work with and that signifi-
cant achievements in access to effective malaria treat-
ment can be made in a short period of time [8,9,15-20].
However, a central criticism of the AMFm mechanism
was that a substantial share of subsidized, private sector
ACT was likely being taken by patients without malaria,
since many private outlets do not offer diagnostic testing
[21]. The reach of the private sector with respect to
ACT treatment—combined with its limitations with re-
spect to targeting of ACT to malaria-positive patients—
has fuelled an interest in scaling up diagnostics through
private sector channels.
Several pilot programmes have experimented with intro-
ducing rapid diagnostic tests (RDTs) for malaria in private
sector clinics and drug shops [12,22-24]. RDTs for malaria
have attracted interest in recent years because of their high
sensitivity, specificity and simplicity for use in resource-
poor settings. An RDT requires the tester to collect one
drop of blood through a finger prick and place it onto a
small plastic device called a cassette, which displays the re-
sult of the test within 15–20 minutes. The correct and safe
administration of RDTs by non-medical personnel is well
documented in the literature [24-29]. RDTs could shrink
the gap in diagnostic testing rates by extending parasito-
logical confirmation of malaria to communities without
access to microscopy or to areas where barriers to mi-
croscopy exist.
Increasing availability of RDTs in the private sector
has great potential for improving diagnosis and treat-
ment but introduces a number of challenges on both the
supply and demand side. Operational challenges from
the supply side include ensuring that private providers
transport, store, administer and dispose of the tests and
accompanying materials (lancets, etc.) properly [30]. The
private sector in most malaria endemic countries is
highly variable in quality—from licensed pharmacies and
professionally-run clinics to informal drug shops—and
notoriously challenging to monitor and regulate. Several
studies have demonstrated that private sector providers
perform very well in the domains of RDT transport,
storage and administration [24,31,32] but have found
variation in adherence to the test results with respect to
medication dispensing (Obinna Onwujekwe, personal
communication;[33-35]). Introducing RDTs into the pri-
vate sector also raises questions about provider incen-
tives to offer the tests. Cohen and Dickens show in a
theoretical model that there can be strong profit incen-
tives to private providers offering RDTs and Hutchinson
et al. [36,37] show, in a qualitative analysis, that private
providers may want to offer the tests because of the rep-
utational benefits and because it allows them to offer a
higher quality of care.
Private sector RDT scale up also introduces a number
of challenges on the demand side. Patient demand for
and valuation of testing—less critical for public sector
scale up–become central to private sector introduction.
In particular, people have to see the need for testing, the
value in it and be willing to pay for it. Generating private
demand for public health products can be complex, and
techniques for bolstering demand include commercial
and social marketing, branding, packaging and behaviour
change communication. Encouraging testing for malaria
requires overcoming a longstanding belief that all fevers
are likely to be caused by malaria, fuelled partly by pre-
vious malaria guidelines emphasizing the treatment of
all febrile children with anti-malarials [38,39]. More gen-
erally, patients, caregivers and health care providers
often feel capable of diagnosing malaria based on symp-
toms, which can diminish the demand for testing.
Existing research on patient and provider perceptions
of RDTs available to date has identified a range of socio-
cultural barriers to RDT uptake, including lack of confi-
dence in test results or the person administering the
test, fear of high cost of testing, fear of undisclosed HIV
testing, risk aversion to not treating a potential malaria
illness coupled with a belief that ACT does not have
negative side effects, confidence in oneself to know the
signs and symptoms of malaria and properly treat it
without medical consultation, and rejection of blood
testing as a tool for diagnosis of disease [23,40,41].
Although patients and caregivers often express a high
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level of enthusiasm for RDTs, trust in the test may be
limited by the expectation that the diagnosis will align
with the patient’s own self-diagnosis or a belief that
the test will result in diagnosis of any illness, beyond
just malaria [12,42,43]. This study builds on this litera-
ture by focusing on the determinants of and barriers to
demand for RDTs in private sector drug shops. It goes be-
yond assessing feasibility and acceptability of RDTs in
drug shops to explore whether the foundational elements
of willingness to pay are present in communities in east-
ern Uganda.
In Uganda, malaria is highly endemic and a leading
cause of morbidity and mortality, especially amongst chil-
dren [44]. Due to the lack of availability and convenience
of diagnostic facilities in Uganda, presumptive treatment
of malaria is very common [9]. The private sector, includ-
ing private clinics, pharmacies and small drug shops,
serves the majority of people seeking treatment for febrile
illnesses in Uganda [9,45-47]. However a recent survey
found that only 21% of private, for-profit outlets had mal-
aria diagnostic tests available [8]. In order for Uganda’s
National Malaria Control Programme to meet their na-
tional target of 90% of all suspected malaria cases to re-
ceive confirmatory diagnosis by 2015, use of diagnostic
technology for malaria in the private sector will need to be
increased.
This qualitative study was conducted as part of a larger
project investigating the feasibility and impact of RDT dis-
tribution via private sector drug shops in Uganda [24]. As
part of the implementation strategy, a behaviour change
communication (BCC) campaign was planned to encour-
age and sustain the demand for RDTs in drug shops in
Uganda. While incentive alignment and behaviour change
on the supply side are crucial to RDT introduction as well
[36], this campaign was focused on demand creation from
the patient/community and thus the focus groups probed
most specifically into foundational elements of demand.
These results describe the findings of a qualitative assess-
ment that was conducted in order to inform and design
the BCC strategy.
Methods
Study design and questionnaire
The primary objective of this study was to explore the
following research question: What are the barriers and
incentives to purchasing malaria diagnosis among pa-
tients and what recommendations can be made for
boosting demand for RDTs introduced into the private
sector, particularly in drug shops? Focus group discus-
sions were conducted with community members to ex-
plore both community practices and perceptions around
malaria diagnosis. The field guide questionnaire included
both very open-ended questions such as “What do
people in this community think about blood testing for
malaria?” and “How do people in your community know
when they have malaria?”, and more targeted questions
such as “Often people take malaria medicine without be-
ing tested. Why?” More targeted questions were derived
from an expected utility framework for malaria diagnosis
(discussed below) and, combined with open-ended ques-
tions, were designed to also uncover additional barriers
to demand for RDTs. Broad themes explored included:
why people do or do not seek diagnosis for malaria, how
people react to test results and why and what can be
done to increase the use of diagnostic testing and, in
particular, RDTs.
Sites, sampling and timeline
A total of eight focus group discussions (FGDs) were
conducted in Uganda’s Eastern Province between 28
November and 28 December, 2011. Six districts of eastern
Uganda were selected as sites for the study: Budaka,
Bukedea, Kibuku, Kumi, Ngora, and Pallisa. Figure 1
shows the spatial location of the eight focus groups.
Six focus groups were conducted with female partici-
pants and two with male participants after informed con-
sent was secured. For each focus group, 10–12 participants
were recruited with the help of local community leaders,
with a particular focus on adults with children under the
age of five. For the female focus groups, participants were
rural women from age 18 to 50, identified as either preg-
nant or caregivers of children. Male participants were be-
tween age 18 and 56 and either fathers or caretakers of
children.
Table 1 summarizes the gender and age distribution
of focus group participants. A total of 62 women and
22 men participated in the focus group. Given the ex-
plicit focus on participants with children, the majority
of participants were age 30 and older; the average
number of children in their household was 4.4.
Training, data collection and translation
Field teams were provided with a three-day training on
qualitative methodologies and ethical issues. Researchers
were divided into teams of one supervisor and two re-
search assistants for data collection; each team was re-
sponsible for two focus groups. Qualitative interview
guides were prepared in English, then translated into Lu-
ganda and Ateso and piloted prior to data collection.
Focus group discussions were audio recorded; recordings
were then transcribed and translated into English for
analysis. All fieldwork was conducted by Uganda Health
Marketing Group. While exact transcripts of FGDs were
requested, transcriptions provided to the researchers in-
cluded some places where the translation appeared to
summarize responses. In effect, the FGD translations in-
clude a combination of exact translated transcript and
meaning-based translation.
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Data analysis
Data were analysed using open coding to identify recur-
rent themes, which were then grouped into categories
using axial coding to connect related concepts. Five cat-
egories emerged and were framed as “potential barriers
to malaria diagnosis,” based on the theoretical frame-
work described in the next section. NVivo version 9
(QSR International) was used to manage the data through-
out coding and analysis.
Analytical framework
The theoretical starting point for this study was an ex-
pected utility formulation of demand for RDTs as derived
in [36], where demand is a function of the expected bene-
fit minus the expected cost to testing, relative to the ex-
pected costs and benefits of presumptive treatment with
anti-malarials. This framework is broad enough to incorp-
orate a number of crucial elements of the testing decision:
1) the direct and indirect costs such as the cost of the tests
and medicines, the time cost of seeking care, and the
health and productivity costs of untreated illness; 2) direct
and indirect benefits such as health and productivity gains
to wellness and psychological benefits to a confirmed
diagnosis; and 3) health beliefs and risk perceptions such
as the subjective assessment of the likelihood that an ill-
ness is malaria, the belief in the accuracy of the test and
Figure 1 Spatial location of focus groups.
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the belief that the illness, if found not to be malaria, is
something serious that needs treatment. Other utility
costs include, for example, fears of testing and suspicion
that the test detects HIV. While barriers to and enablers
of RDT demand stemming from this framework were ex-
plored in the FGDs, the FGDs aimed to elicit additional
barriers that are not naturally part of this framework or
had not appeared in previous literature through very open
ended questions. Based on the theoretical framework and
the results of the FGDs, we grouped potential barriers to
RDT demand into five broad categories:
Potential Barrier 1 Lack of understanding about malaria
testing
The first potential barrier to patient uptake of malaria
diagnosis explored is related to knowledge of the disease
and understanding of the role of testing and treatment.
In order to seek testing for malaria, a patient must pos-
sess a certain amount of knowledge about the disease,
including knowing that malaria exhibits recognizable
symptoms, is detectable by microscopy or RDTs, and is
treatable with appropriate medication. If a patient or care-
giver lacks understanding in any of these areas, this could
reduce the likelihood of seeking diagnosis for malaria.
Potential barrier 2 lack of perceived need for diagnosis
The second potential barrier explored is related to a pa-
tient’s perceived need for diagnosis. In order for a person
to seek testing, s/he must understand that symptoms of
malaria overlap with symptoms of other diseases, and
must believe that a test is necessary to determine whether
or not malaria is present. This requires some degree of
uncertainty about one’s malaria status (i.e., not complete
confidence in one’s ability to self-diagnose). A perceived
need for diagnosis also requires a belief that knowing one’s
disease status is important and that there is value in the
information provided by the test (e.g. that it could save
one from having to seek additional care in the future).
Potential barrier 3 perception that the test/provider lacks
credibility
A third potential barrier to patient demand for malaria
diagnosis is the perceived credibility of the test and of
the provider. If a patient perceives the test to be unreli-
able or does not trust the provider to deliver the results
honestly, then a patient may lose confidence and avoid
testing. If patients perceive the test to be accurate and
trust the provider, then they may be more likely to seek
testing.
Potential barrier 4 perception that the cost of testing is
too high
The fourth potential barrier to patient adoption of mal-
aria diagnosis is related to the perception that testing
comes at too high a cost, both monetary cost and time
cost. Simply put, a patient will not seek testing if s/he
feels s/he cannot afford it or that it is not worth the cost.
The out-of-pocket payment at a private facility, the time
and expense of travelling to and waiting at a health facil-
ity, and health centre visit fees are all potential deter-
rents for a patient seeking testing. Even though testing
has the potential to save the patient money (by helping to
avoid the cost of incorrect medications) and time (by pre-
venting repeat visits for treatment), the perceived up-front
monetary and time costs of seeking testing may remain a
deterrent.
Potential barrier 5 fear of testing
The last potential barrier explored is fear of testing, in-
cluding fear of needles, fear of having blood drawn and
fear of privacy violations such as unknowingly being
tested for HIV.
Ethics statement
Ethical approval for this study was given by the Harvard
School of Public Health (IRB Protocol # P19371-106)
and the Uganda National Council for Science and
Technology (Protocol # HS805).
Results
The results of this study shed light on the five potential
barriers to patient demand and willingness to pay for
malaria diagnosis noted above. For each potential bar-
rier, obstacles that have been overcome and obstacles
that remain were differentiated.
Potential barrier 1 lack of understanding about malaria
testing
FGDs indicated that knowledge of malaria, its symptoms
and its ability to be treated is common throughout the
community. In every focus group, respondents identified
malaria as one of the most common illnesses in the
community. Respondents noted a wide range of symptoms
Table 1 Sample composition
Females
15-29
Females
30-59
Males
15-29
Males
30-59
Average
number of
children
Budaka District FG 1 2 10 0 0 6.2
Budaka District FG 2 0 0 5 7 2.8
Bukedea District FG 1 7 3 0 0 3.7
Bukedea District FG 2 0 0 4 6 4.6
Kibuku District FG 1 2 8 0 0 5.2
Kumi District FG 1 4 6 0 0 3.8
Ngora District FG 1 3 7 0 0 4.4
Pallisa FG 1 4 6 0 0 4.8
Total 22 40 9 13 4.4
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thought to be associated with malaria, including fever
or high body temperature, headache or body pain, lack
of appetite, weakness or tiredness, nausea, vomiting or
diarrhoea, chills or coldness, and cold-like symptoms
including runny nose, coughing or sneezing.
The most common illness here is malaria. – 30-yr-old
female, Budaka
A person [who has malaria] will feel a lot of coldness,
high fever, body and joint pains, running nose, body
weakness and no appetite for food. – 28-yr-old female,
Kumi
If you see a child with persistent high body
temperature and feeling cold, having no appetite and
shivering then you will know for sure that child has
malaria. – 25-yr-old male, Bukedea
Participants also showed a general familiarity and
comfort with malaria testing as a common part of
treatment, and demonstrated good knowledge of where
testing is available in their communities. Common
places to obtain testing and treatment for malaria were
government health facilities and private clinics.
Last time I had malaria I first felt headache and lost
appetite, then felt general body pain and body weakness.
When I went for a test it was malaria. – 50-yr-old
female, Pallisa
Most of us go to the government health centre for
blood testing. – 20-yr-old female, Bukedea
Those who have money go to clinics to test for
malaria. – 24-yr-old female, Pallisa
Although these results indicate that knowledge about
malaria testing and treatment is widespread, one remaining
obstacle to ensuring community understanding of malaria
testing is a general lack of familiarity with RDTs. The ma-
jority of focus group participants had never heard of RDTs,
with the exception of four individuals (out of 80 total
participants). Those few who had heard of RDTs (typ-
ically referring to them as “malaria strips”) knew that
they were being used in private clinics to test for mal-
aria and that test results were available in about 10–25
minutes. Overall, participants seemed to have difficulty
distinguishing between RDTs and microscopy, most
likely because both involve collecting a drop of blood
and placing it on a medical device.
We have never heard of rapid diagnostic tests. We
only know the one where they prick and put blood on
the slide. – Budaka
Is rapid diagnostic test for malaria a person, or what
is it? – 50-yr-old female, Kibuku
Potential barrier 2 lack of perceived need for diagnosis
The study showed that community members understand
that malaria has similar symptoms to a number of other
diseases. Specifically, malaria was described as having
similar symptoms to HIV/AIDS, measles, and typhoid,
as well as tuberculosis, syphilis and cold/flu.
"Moderator: What other illnesses could it be when it
seems to be malaria?
Respondent 4: Typhoid is an illness which has all
symptoms like those of malaria because you will have
continuous headache, vomiting and lack of appetite.
R10: Measles also is like malaria in that when a child
has measles s/he will have no appetite, will have
general body weakness, headache, vomiting and even
diarrhoea, and all these are similar to malaria
symptoms.
R6: Even HIV/AIDS brings up symptoms like those of
malaria. A person will feel persistent headache, feeling
cold, having high body temperature and lack of
appetite.”
– Female FGD, Pallisa
Many respondents described experiences in which
they thought they had malaria but it turned out to be
something else. The practice of self-diagnosis was a re-
current theme across focus groups, and many people
described self-medicating when they exhibited familiar
symptoms that they had associated with the disease in
the past. In many cases, participants described having
bought medication that proved ineffective in relieving
their symptoms, and in turn described numerous
courses of action they would take, such as visiting a
different clinic, requesting a blood test, or visiting a
traditional healer. Participants in every focus group
said that they had had the experience of thinking they
had malaria because the symptoms were familiar and
then discovering that they did not have it after being
tested.
I used to have a constant headache and I thought it was
malaria but when I tested it was typhoid. – 20-yr-old
female, Pallisa
I have had a personal experience in this. I had
symptoms of malaria and went to test for malaria
parasites but the health workers told me that there
was nothing. I have also seen some other people who
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thought they had malaria when it wasn’t. – 26-yr-old
male, Budaka
I will now go to the doctor so that they will do blood
testing to find out what sickness it really is, whether
it’s malaria or not since I have previously been taking
drugs not knowing what I am suffering from. – 30-yr-old
female, Budaka
I only begin worrying if the malaria treatment does
not heal me, then I think it may not have been
malaria…if I was given medicine from the clinic I will
change and go to the government health facility for the
test. – 19-yr-old female, Bukedea
If I see that I am not getting better, I will go for a
blood test for malaria before I continue with any
treatment. – 45-yr-old female, Budaka
Community members expressed a general belief that it
is important to get tested for malaria before starting
treatment. They explained that testing is important in
order to know which disease is present and to obtain the
correct medication rather than wasting time treating the
wrong disease and thereby prolonging illness. Some
people even expressed concern regarding the practice of
self-medication, which shows again that community
members are aware that self-diagnosis can fail.
It’s good to test blood first before you get treatment
because after testing you will know the right treatment to
take rather than guessing. – 33-yr-old female, Bukedea
One bad thing of not testing for malaria is you will
waste time treating what you don’t know and you
won’t get well. – 50-yr-old female, Pallisa
There is a problem of self-medication where most
people say they know their sickness hence no need to
test. – 30-yr-old male, Bukedea
Beliefs about the effects of taking anti-malarials when
the disease is not present were mixed. While some partici-
pants explained that it is a good idea to take anti-malarials
as prevention for malaria, many people mentioned poten-
tial dangers of taking malaria medications if the disease is
not present, including side effects, disease, overdose and
death.
It is good to take medicine as a preventive measure
against malaria. – 50-yr-old female, Kibuku
“M: Can you think of some negative or positive effects
of taking malaria medicine if you don’t have malaria?
R4: For me taking malaria medicine when you don’t
have malaria brings nausea and at times vomiting
and dizziness. I have a personal experience with this
when I tested negative for malaria and health providers
gave me medicine to take. I really had a bad experience.
R1: When a person keeps on taking drugs when s/he
does not have the sickness, it will weaken the
immunity in his body such that next time when s/he
falls sick, the drugs may not work because s/he has
been previously using them even when s/he is normal.
Not only that but when you fall sick next time you will
be put to another level of treatment.
R10: The bad thing of swallowing drugs when you’re
not sick is that your body is affected in a way that you
become immune to anti-malarials.
R5: For me I see that when you swallow drugs [when
you do not have malaria], you will put your life at
risk. Anything can happen to you as a result of taking
those drugs.
M: Anything else gentlemen? I have not heard anyone
mention any positive reasons to taking malaria
medicine when you don’t have malaria.
R(ALL): I don’t really think there is anything positive
about it because one’s life will be put in danger.”
- Male FGD, Budaka
Interestingly, most participants also stated that there
are scenarios when malaria testing is not necessary. In
cases of severe symptoms, such as when a child falls very
ill in the middle of the night, participants stated that
they would be taken to the hospital for immediate treat-
ment, and that often the provider would skip testing in
order to expedite treatment. This would be the appropri-
ate protocol in cases of suspected severe malaria. Partici-
pants also described that there is no need for testing
when the symptoms are familiar and they are confident
that they have malaria. One participant also mentioned
that testing is unnecessary during the dry season when
mosquitoes are not present.
People often get signs of malaria whenever they have
it, so you find that they don’t bother to test
themselves because they always know when they have
malaria. – 34-yr-old male, Budaka
Normally when you go to the health centre when the
child is very ill, they will be put on a drip immediately
and test for malaria later. – 26-yr-old male, Budaka
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Despite a general community understanding that mal-
aria symptoms can appear similar to those of other dis-
eases and a belief that knowing one’s disease status is
important, people often still self-medicate and wait to
see if their treatment is effective before seeking testing.
Even though many people have had the experience of
misdiagnosing themselves with malaria and only learning
their true diagnosis after testing, they often rely on test-
ing only as a secondary strategy.
Potential barrier 3 perception that the test/provider lacks
credibility
Respondents seemed to reflect a confidence in diagnosis-
based treatment at public facilities, which were generally
preferred over private clinics. Government health facilities
were preferred for what was perceived to be honest and
well-trained staff, high quality drugs and services, and re-
ferral capabilities. Respondents mentioned that govern-
ment facilities give the correct treatment, do not provide
expired drugs, and provide more effective drugs, as com-
pared with private clinics. Participants also mentioned that
the government health facilities are able to refer patients
to bigger hospitals when the condition is serious. While
respondents generally seemed to trust government health
facilities, results of the study showed some degree of dis-
trust in private providers. In a few instances, participants
reported that private clinics were dishonest and would sell
expired medications or lie about test results in order to
sell more medications and increase profit.
“M: Which places do you trust most?
R9: I trust government health facilities because health
provides there are always honest and trained but in
clinics since it’s business they can lie that you have
malaria because they want money.
R3: I trust government health facilities because if they
have drugs they can give for free.
R2: I trust government health facilities because if they
have trained staff they also have better equipment and
if you condition is worse they can refer you to a
hospital.
M: Anything else?
R10: We always use both clinics and government
health facilities.”
- Male FGD, Bukedea
Participants described malaria diagnosis as typically con-
sisting of the provider taking an oral history, performing a
physical examination, taking vitals, and ordering a blood
test for malaria. Most participants agreed that if a provider
does not test for malaria during a visit, it is due to the fact
that there is no indication of malaria. In most cases, pro-
viders were reported to have explained test results to pa-
tients. However, a few respondents described receiving a
blood test and being given medications without ever being
told whether or not they in fact have malaria.
In the consultation room the health provider will first
take your history – how old are you, what is the
problem, when did it begin – and sometimes he checks
you using a thermometer then later sends you to the
laboratory for a blood test. – 40-yr-old female, Pallisa
If you get a good doctor, he will tell you what your
illness is but others will just treat you and you go back
home without knowing the disease. – 26-yr-old female,
Kumi
A few participants also reflected a possible lack of con-
fidence in test results. Many respondents discussed hav-
ing taken malaria medications even after receiving a
negative blood test result, either because the provider
still prescribed it or because they still felt sick and
bought medication anyway. In this scenario, participants
cited various perceived benefits of taking medication, in-
cluding prevention of malaria and “just in case” malaria
is “hiding” in the body. The desire to take medication in
case the test failed to detect malaria suggests a belief
that the test is not always effective at detecting malaria.
Perceived credibility of the provider and test was mixed.
While participants generally expressed trust in public fa-
cilities, there was some degree of distrust in private facil-
ities. Some patients also questioned the reliability of the
test, citing experiences when they took anti-malarials
even after a negative test result, reasoning that the mal-
aria could be “hiding.”
I was tested and found that I do not have malaria but
I was again given drugs reasoning that the malaria
might be hiding. – 30-yr-old female, Kumi
When you are not feeling well and you test negative
you will still have a feeling that malaria might be
hiding so you continue taking malaria drugs. – 37-yr-old
male, Bukedea
Potential barrier 4 perception that the cost of testing is
too high
Perceptions of time and monetary costs were reflected
in patients’ preferences for seeking care at government
health facilities versus private clinics. Results indicated
that the monetary cost of testing, including fees for
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visits, supplies, medical record books, and the test itself,
remains an important barrier for patients seeking testing.
Respondents described private clinics as being the most
expensive option.
If you don’t have money no clinic can ever give you a
free test. – 26-yr-old female, Pallisa
In clinics when you go they ask you what the problem
is and if it is malaria related they ask if you have
money for a blood test. – 19-yr-old female, Bukedea
Many participants preferred seeking care at government
health facilities due to the fact that they provide free ser-
vices. However, in some cases, government health facilities
were also faulted for charging fees even though user fees
were abolished in the Ugandan public health system in
2001 [48]. In one district, numerous respondents men-
tioned that at government health facilities they were asked
to buy syringes and gloves in order to receive testing for
malaria.
People prefer going to a government health facility
because they get free treatment and they are given
right dose of treatment. – 21-yr-old female, Bukedea
Sometimes you go to the health centre and find that
they need money for the record book and for testing
blood and yet you do not have the money. – 38-yr-old
female, Ngora
When you go to the government facility and you are
sent for a blood test the laboratory assistant will ask
you for money for buying gloves and syringe for
testing your blood and if you do not have it you are
told to go back home then come back. – 43-yr-old
male, Bukedea
Time costs were equally as important as monetary costs,
and were reflected in a different set of preferences re-
garding providers. Respondents described multiple time-
related barriers to accessing care at government health
facilities, including distance and long lines/wait times.
Government facilities were described as being farther
away and more difficult to reach on foot as compared
to private clinics. Many patients described difficulties
in reaching these facilities due to transportation costs
and the burden of carrying small children along the
way. Additionally, long lines and wait times were com-
mon and sometimes prohibited people from accessing
care. Many respondents mentioned that the health centres
often experience drug stock-outs and refer patients to pri-
vate clinics to purchase medicines, an additional delay for
patients accessing care.
It takes six miles to reach the health facility and when
you reach the hospital the line is long so you spend
the whole day in the hospital without getting
treatment. – 50-yr-old female, Kibuku
These days I just go to the clinic to test and get
treatment because when you go to the health centre
they only prescribe treatment for you and they tell you
that they don’t have drugs and then they send you to
the clinic to buy the drugs. – 26-yr-old female, Pallisa
In contrast, private clinics offered faster service, longer
hours, and close proximity to the community, all factors
that help patients to save time. Participants described
that while government health facilities can have long
lines and long wait times, at private clinics patients re-
ceive care without delay. They mentioned that some-
times government facilities open late or close early,
while private clinics are generally open longer hours on
a more consistent basis.
I trust private clinics. They are always conscious about
time – they don’t keep you waiting for long. They also
they know how to monitor and care for their patients.
– 26-yr-old male, Budaka
If you are badly off sometimes you will go to the health
unit and find that there are very many people, so in
order not to wait you will go to the clinic which also
does testing and there aren’t very many people so you
will be attended to immediately. – 50-yr-old female,
Ngora
Patients described prioritizing treatment over testing
when faced with limited resources. In many cases people
preferred to spend what money they had on medications
rather than testing, for fear that purchasing a test would
prohibit them from being able to afford the necessary
treatment. Many people also said that they were unable
to make the journey to the health centre and could not af-
ford transportation to get there, so it was easier to buy
medications at a local clinic or drug shop. There was no
mention of the possibility that testing could save money by
potentially avoiding the cost of inappropriate medications.
Lack of money is what makes people get treatment
before testing…a person will debate that they only
have a little money and if they waste it on testing
blood, then they will not have enough money for
drugs…people prefer buying drugs. – 37-yr-old male,
Bukedea
The health centres which test are very far and
sometimes there is no money for testing. So, if you are
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badly off you will first seek treatment before testing
from the nearest clinic. – 31-yr-old female, Kumi
For example I have two young children, one age one
year and another three years. It is difficult to carry
both to go to the health centre so I end up treating
them without testing. – 36-yr-old female, Budaka
Cost, both time and monetary, remains a complicated
and important barrier to malaria testing, as all partici-
pants cited a variety of testing fees, transportation costs
and time costs that influence their decision to seek mal-
aria testing. Generally financial costs were lower at pub-
lic facilities, which were more likely than private clinics
to provide free services. However, private clinics were
more easily accessible than public facilities, therefore
presenting a lower time cost. Faced with limited re-
sources, patients were likely to pay for medications be-
fore testing.
Potential barrier 5 fear of testing
While no fear of needles or blood drawing emerged from
the focus groups, some participants expressed fear that a
provider would use the blood test to perform HIV testing
without consent. In addition to exposing the fear of know-
ing one’s HIV status, this example also reflects a degree of
distrust in providers and highlights a remaining barrier,
ensuring patient confidentiality in all testing venues.
Some people think that when they go get tested for
malaria in the health centre, they will also be tested
for other diseases like AIDS. So they prefer taking
drugs rather than getting tested and knowing their
HIV status. – 50-yr-old female, Ngora
Some people fear to know the results of the blood test
as if it is an HIV test. – 50-yr-old female, Kibuku
Discussion
The scale up of diagnostic testing is now a central com-
ponent of malaria policy and is a cornerstone of effective
and efficient case management. For some countries and
contexts, the private sector will likely not play a major
role in this scale up, as treatment-seeking in this sector
is minimal and/or the challenges to private sector en-
gagement (regulation, monitoring, etc.) are currently too
substantial. In other countries, however, where there is
heavy reliance on the private sector for malaria treat-
ment, strategic engagement of private sector providers
will be essential to the ability to attain universal access
to diagnostic testing. Overall, the effectiveness and cost-
effectiveness of private sector RDT strategies will depend
on a country’s endemicity and treatment-seeking profile
[49]. A recent Cochrane Review of the impact of RDTs
on fever case management came to the conclusion that,
while RDTs have great potential to reduce unnecessary
usage of anti-malarials, they may not lead to significant
improvements in morbidity and mortality [50]. The eco-
nomic and health impact of RDTs will clearly depend
crucially on the disease profile and the treatment-
seeking behaviour of local populations.
Several pilot programmes have been implemented re-
cently or are underway exploring the feasibility and im-
pact of private sector provision of RDTs in Africa. Short
of making testing in the private sector a legal require-
ment (which could be excessively difficult and expensive
to enforce in a number of countries/contexts), successful
scale-up of RDTs in the private sector will require that
patients view RDTs as a valuable commodity, with cred-
ible and useful information that can be used to guide
treatment and for which they are willing to pay, despite
very limited resources. This study was designed to ex-
plore potential barriers to uptake of malaria diagnosis in
eastern Uganda with the objective of understanding how
to design successful behaviour change campaigns and
supporting interventions for programmes and policies
scaling up private sector RDT distribution.
Participants mentioned several reasons why they felt
diagnosis was important. One reason was that symptoms
of non-malarial illnesses can appear like malaria. Partici-
pants noted times when they thought they had malaria
and discovered they were wrong. The belief that one can
be wrong in his or her assessment that an illness is mal-
aria is a critical precondition for valuing the RDT. A
common concern in scaling up malaria diagnosis is that
people will not value or accept the test because they are
very confident in their ability to self-diagnose based on
symptoms (especially fever). While participants did seem
to place quite a bit of confidence (perhaps overconfi-
dence) in their ability to know when an illness is malaria,
overall the results from our focus group discussions sug-
gest that people are aware that they can be mistaken and
do feel uncertainty in their assessments about malaria
status. Emphasizing that not all fevers are malaria thus
may be necessary but not sufficient foundation for a
BCC strategy. Some communities may already appreci-
ate the overlap between malaria and other illnesses and
may be choosing to forego diagnosis for other reasons.
Another common concern regarding potential demand
for malaria testing is that the perceived costs of taking
malaria medicine when it is not needed are low. The
more concerned patients or caregivers are about the
costs of taking unnecessary medication, the higher the
valuation of an RDT should be. A number of participants
mentioned potential dangers of taking anti-malarials
when they are not needed, including side effects. While
side effects did seem to be a concern, participants did
not mention other potential costs of taking unnecessary
medication. This is somewhat surprising, considering
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how resource constrained these households are. Partici-
pants also did not mention concerns about unnecessary
medication leading to delays in treatment for the true
cause of illness. While it is possible that these potential
benefits of RDTs have simply not been considered in
these communities, it suggests that these themes may
not resonate in certain communities and may be inef-
fective as cornerstones to a BCC strategy emphasizing
malaria testing.
Overall, participants were very familiar with malaria
diagnostic testing and where testing could be obtained.
Despite a familiarity with testing and knowledge of its
importance, the prevailing community practice is typic-
ally to seek testing only when presumptive treatment
proves ineffective. This has been found in other recent
qualitative research on RDTs in Uganda [23]. The use of
testing as a secondary strategy suggests that neither the
perceived benefit of diagnosis, nor the perceived cost of
incorrect treatment, is significant enough to lead a pa-
tient or caregiver to seek testing first, although appar-
ently the benefits of diagnosis appear more salient to
patients after presumptive treatment has failed. This
suggests that the monetary and time costs associated
with testing are significant barriers to demand for mal-
aria diagnosis. Many participants mentioned the diffi-
culty and inconvenience of testing. Taken together, this
suggests that BCC campaigns may want to emphasize
the convenience and ensure the affordability of RDTs in
the private sector, their proximity to households, the
speed with which results can be acquired, etc.
The focus groups showed that when faced with limited
financial resources, patients generally prefer to spend their
money on treatment rather than testing. They expressed
concern that they may be unable to afford treatment if
they purchase a test first. Even in public facilities, where
testing and treatment are supposed to be free in Uganda,
fees are often charged for testing equipment (e.g., gloves
and syringes) and medications can be stocked out, requir-
ing the patient to purchase medication in the private sec-
tor. Transportation costs, wait times and convenience
were also drivers of individual decision-making. In the
case of a young child falling ill in the middle of the night,
a parent might accept higher fees at a drug shop because
it is more convenient given the urgency of the situation.
An important finding to keep in mind is that despite
widespread knowledge of malaria testing, familiarity with
RDTs was limited. This suggests, and may be due to the
fact, that many people have not encountered RDTs. In a
household survey conducted for a different aspect of this
project with a representative sample of the local popula-
tion (see [24]) only 25% of respondents had heard of
RDTs. Public health facilities in the area were also sur-
veyed as part of this project and, at the time of the focus
groups, roughly 50% of facilities had RDTs in stock.
Thus, while RDTs were a somewhat new technology at
the time, they had already been rolled out to a signifi-
cant share of public facilities though were very rarely
available in drug shops. Very few participants had actu-
ally heard of RDTs, so the majority of opinions about
malaria testing were based on experiences with what
was perceived as microscopy – in practice distinguishing
RDTs from microscopy may not be easy for patients due
to the common finger-pricking procedure. While the
focus groups showed that patients are sometimes scep-
tical of test results, and occasionally continue taking
anti-malarials after a negative test, it is important to
keep in mind that these opinions were generally based
on experiences with microscopy.
Despite the remaining barriers, a general lack of famil-
iarity with RDTs may actually present an opportunity to
tip the scale towards adoption of RDTs. Interventions
promoting RDT sensitization and education, combined
with increasing the availability and affordability of RDTs
in private sector drug shops, could help to promote
RDTs as a reliable, inexpensive and convenient source of
diagnosis. A patient who prefers not to seek testing due
to the long travel and wait times in the public sector
may be pleased to learn that testing by RDTs eliminates
both of those barriers. However, sensitivity to cost must
be kept in mind. Both because people may have limited
financial means and because ACT is heavily subsidized
in many places, it may be appropriate and necessary to
heavily subsidize RDT sales in the private sector [36].
The results in this study may not be generalizable
across all contexts. First, the level of malaria prevalence
is quite high in this region (nearly 50%) [34]. A high
level of malaria prevalence to some extent decreases the
value of the test, since the likelihood that the test can
allow the patient to avoid unnecessary medications is
lower. If people in this community are used to testing
positive, they may see less reason to continue being
tested in the future. On the other hand, this study and
others [23,51] have found that patients place a high value
on knowing the source of illness, particularly if it confirms
their expectations. A positive RDT result would enable a
patient or caregiver to be sure that she was treating the
correct illness and in that sense may increase valuation of
the test. If positive results build confidence in and valu-
ation for testing, RDTs may actually be more successfully
introduced to high endemicity settings.
Further, the FGDs took place during the AMFm pilot
programme in which ACT was heavily subsidized in the
private sector and drug shops. This programme substan-
tially reduced the price of ACT, the recommended first-
line treatment for malaria, and made it much more
widely available in this area [8,15]. The value of a diagno-
sis could also be reduced when ACT is more affordable
[36]. Finally, patient demand for RDTs could depend
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substantially on the major causes of non-malarial illnesses
in an area. If people tend to presumptively treat for mal-
aria and then test only if treatment fails, they will most
often never need to test if the illness was either malaria
(as it is in high prevalence settings) or was a simple self-
limiting virus. These types of illnesses that will simply re-
solve on their own over time tend to be the major cause
of non-malarial fever [52].
Conclusions
Results from our FGDs suggest that, at least in contexts
such as eastern Uganda, private sector RDTs will have to
be made affordable and convenient in order for a sub-
stantial share of patients to pursue testing as a first
course of action for suspected malaria. This may mean
subsidizing the tests and distributing them through retail
establishments that reach remote areas, so the tests can
be as accessible and convenient as possible to rural com-
munities. Enhancing the credibility of providers, for ex-
ample, through accreditation programmes, could help
communities trust test results from these establishments.
Private sector RDT programmes may need supporting
interventions, such as subsidies and behaviour change
campaigns in order to reach substantial scale. It is pos-
sible that these interventions need only take place early
in the programmes as demand for RDTs grows. Overall,
private sector markets and foundational elements of
demand for testing are likely to vary widely across
malaria-endemic settings, and more research is needed
to understand how to boost testing throughout malaria
vulnerable populations.
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